Overcome the challenges in orphan drug development with modeling and simulation
Developing drugs for rare diseases poses a range of clinical, regulatory and commercial challenges. The small number of patient populations are difficult to identify and recruit for clinical trials.
We have supported the approval of over 100 orphan drugs, including over 90% of new novel drug approvals with orphan designation in the past 6 years by the US FDA with our software or services. As the global leader in model-informed drug development, we have worked on more rare and orphan drug development programs than any other consultancy.
Visit our Rare Disease Resource Center Here:
Challenge: Small patient pools
Solution: Our expertise in clinical pharmacology strategy and modeling and simulation (M&S) services enable us to quantify drug-disease-trial and exposure-response models from small patient populations providing insights into biomarkers and endpoints.
Challenge: Sensitive patient populations
Solution: We can model the impact of a drug in development on other disease states or untested populations. These proven quantitative methods are actively encouraged by global regulators who have demonstrated extraordinary flexibility in approving orphan drugs either through an accelerated approval pathway, the elimination of a second pivotal clinical trial, or applying M&S in lieu of certain trials.
Challenge: Unique regulatory landscape
Solution: Experience in early and careful planning is critical for rare disease development. The Certara regulatory team has more than 200 experts and writers with proficiency in orphan global filings, as well as a deep understanding of how to articulate the results derived from modeling and simulation. We provide quantitative and regulatory expert guidance and active support from pre-IND meetings through clinical development and postmarket approval.
Solution: Certara develops a quantitative Multicriteria-decision analysis-based framework adapted to the very specific issues in rare disease development and access including quality of evidence, disease severity, ethical considerations, population-level factors, economic impact of the disease, and specific budgetary impact. By combining disease information, patient input, real world data, and innovative pricing and contracting strategies with the wider social and health benefits, we build robust, evidence-based results to justify market access and pricing.